Cancer Tumor Profiling Global Market Opportunities and Strategies to 2035

This report describes and explains the cancer tumor profiling market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global cancer tumor profiling market reached a value of nearly $14.97 billion in 2025, having grown at a compound annual growth rate (CAGR) of 13.1% since 2020. The market is expected to grow from $14.97 billion in 2025 to $26.5 billion in 2030 at a rate of 12.1%. The market is then expected to grow at a CAGR of 11% from 2030 and reach $44.74 billion in 2035.

Growth in the historic period resulted from rising global cancer incidence, growing public-private initiatives for cancer screening programs, growing cancer research investments and favorable government support towards cancer research and development. Factors that negatively affected growth in the historic period were high cost and limited reimbursement and regulatory hurdles and clinical validation requirements.

Going forward, adoption of precision oncology, expansion of liquid biopsy testing, growth in targeted therapy development and integration in oncology clinical trials will drive the growth. Factors that could hinder the growth of the cancer tumor profiling market in the future include payer skepticism and policy barriers and lack of trained professional and lab technician and impact of trade war and tariff.

Market trends for the cancer tumor profiling market include liquid biopsy multi-gene panel for comprehensive genomic profiling, emergence of hybrid capture-based comprehensive oncology sequencing platforms, advanced multi-gene cancer profiling solution for precision oncology and emergence of whole exome sequencing-based tumor profiling assays.

The cancer tumor profiling market is segmented by cancer type into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer and other cancer types. The breast cancer was the largest segment of the cancer tumor profiling market segmented by cancer type, accounting for 26.8% or $4.01 billion of the total in 2025. Going forward, the lung cancer segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by cancer type, at a CAGR of 14.4% during 2025-2030.

The cancer tumor profiling market is segmented by technology into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarray and other technologies. The next-generation sequencing (NGS) market was the largest segment of the cancer tumor profiling market segmented by technology, accounting for 36.5% or $5.47 billion of the total in 2025. Going forward, the immunohistochemistry (IHC) segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by technology, at a CAGR of 15.4% during 2025-2030.

The cancer tumor profiling market is segmented by process type into genomics, proteomics, epigenetics and other types. The genomics market was the largest segment of the cancer tumor profiling market segmented by process type, accounting for 42.5% or $6.36 billion of the total in 2025. Going forward, the epigenetics segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by process type, at a CAGR of 15.6% during 2025-2030.

The cancer tumor profiling market is segmented by application into personalized medicine, diagnostics, biomarker discovery, prognostics and research applications. The diagnostics market was the largest segment of the cancer tumor profiling market segmented by application, accounting for 36% or $5.38 billion of the total in 2025. Going forward, the personalized medicine segment is expected to be the fastest-growing segment in the cancer tumor profiling market segmented by application, at a CAGR of 14.4% during 2025-2030.

North America was the largest region in the cancer tumor profiling market, accounting for 43.6% or $6.53 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the cancer tumor profiling market will be Asia Pacific and North America where growth will be at CAGRs of 14.3% and 11.7% respectively. These will be followed by Western Europe and Eastern Europe where the markets are expected to grow at CAGRs of 11.1% and 10.7% respectively.

The global cancer tumor profiling market is fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 14.070% of the total market in 2024. Illumina Inc. was the largest competitor with a 1.809% share of the market, followed by Thermo Fisher Scientific Inc. with 1.745%, F. Hoffmann-La Roche Ltd. (Foundation Medicine) with 1.643%, Caris Life Sciences Inc. with 1.470%, QIAGEN N.V. with 1.466%, Tempus AI Inc. with 1.432%, NeoGenomics Laboratories Inc. with 1.317%, Exact Sciences Corporation with 1.305%, Myriad Genetics Inc. with 0.942% and Veracyte Inc. with 0.941%.

The top opportunities in the cancer tumor profiling market segmented by cancer type will arise in the breast cancer segment, which will gain $3.21 billion of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by technology will arise in the next-generation sequencing (NGS) segment, which will gain $5.32 billion of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by process type will arise in the genomics segment, which will gain $6.36 billion of global annual sales by 2030. The top opportunities in the cancer tumor profiling market segmented by application will arise in the diagnostics segment, which will gain $5.38 billion of global annual sales by 2030. The cancer tumor profiling market size will gain the most in the USA at $4.42 billion.

Player-adopted strategies in the cancer tumor profiling market include focus on strengthening its business through new launches, through new product developments and focus on strategic partnerships to expand their business expertise.

Market-trend-based strategies for the cancer tumor profiling market include focus on developing innovative solutions, such as liquid biopsy-based next-generation sequencing multi-gene panels with integrated molecular analytics, introduction innovative solutions, such as hybrid capture-based comprehensive oncology sequencing assays integrated with cloud-driven bioinformatics platforms, developing innovative solutions, such as next-generation sequencing-based multi-gene oncology panels with integrated bioinformatics pipelines and launch of innovative solutions, such as whole exome sequencing-based tumor profiling assays integrated with advanced clinical decision support analytics.

To take advantage of the opportunities, the analyst recommends the cancer tumor profiling companies to focus on expanding liquid biopsy based genomic profiling and clinical adoption, focus on integrated hybrid capture sequencing platforms, focus on integrated multi-gene genomic profiling adoption, focus on integrated genomic profiling and evidence based decision support, focus on lung cancer tumor profiling for high growth precision oncology demand, expand in emerging markets, continue to focus on developed markets, focus on expanding distribution channels in place strategy, focus on value aligned pricing and reimbursement optimization in oncology diagnostics, focus on physician-centric evidence-based education, focus on multi-channel stakeholder digital outreach, and focus on clinical capability and stakeholder engagement in tumor profiling adoption.

This product will be delivered within 3-5 business days.